Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 75 versus ISOPAQUE 440.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 75 versus ISOPAQUE 440.
HYPAQUE-M,75% vs ISOPAQUE 440
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
Iodinated radiocontrast agent that attenuates X-rays by increasing the iodine content in tissues, providing enhanced visualization of vasculature and organs during imaging procedures.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
Intravenous: 50-100 mL (22.05-44.1 g iodine) as a single dose for CT imaging; intra-arterial: 5-80 mL (2.2-35.28 g iodine) depending on procedure; dose is based on imaging requirements and patient weight.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Terminal elimination half-life is approximately 1.5 to 2 hours in patients with normal renal function. May be prolonged in renal impairment, correlating with creatinine clearance; dose adjustment not typically required for diagnostic procedures.
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Primarily renal excretion via glomerular filtration. Approximately 95% of the administered dose is excreted unchanged in the urine within 24 hours. Less than 5% is eliminated via biliary/fecal routes.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent